ClinicalTrials.gg
CompletedNCT02770807ATTeSTUpdated May 10, 2024Results posted

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

A Phase 3 interventional study of EryDex Low dose DSP and EryDex High dose DSP in Nervous System Disease and Genetic Syndrome, sponsored by Quince Therapeutics S.p.A.. Completed at 22 sites in 12 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Quince Therapeutics S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Study summary

Objectives:

The objective of study was to evaluate the safety and the efficacy of EryDex (Dexamethasone sodium phosphate encapsulated in autologous erythrocytes, using the EryDex System - EDS) at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on Neurological Symptoms in Patients With Ataxia Telangiectasia.

Initial Double-Blind Treatment Period (0 to 6 Months)

Primary Efficacy Objective:

  • Evaluate the effect of EryDex at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on central nervous system (CNS) symptoms measured by the change in the Modified International Cooperative Ataxia Rating Scale (mICARS) from baseline to Month 6 (Visit 9) in patients with ataxia telangiectasia (A-T).

Secondary Efficacy Objectives:

  • Evaluate the effect of EryDex, compared to placebo, on the Clinical Global Impression of Change (CGI-C) in patients with A-T from baseline to Month 6 (Visit 9).
  • Evaluate the effect of EryDex, compared to placebo, on measures of Clinical Global Impression of Severity (CGI-S; structured) in patients with A-T from baseline to Month 6 (Visit 9)
  • Evaluate the effect of EryDex, compared to placebo, on measures of Adaptive behavior measures in patients with A-T by the Vineland Adaptive Behavior Scales (VABS) from baseline to Month 6 (Visit 9).

Safety Objectives:

  • Evaluate the safety and tolerability of two non-overlapping doses of EryDex, compared to placebo, in patients with A-T over the 12-month double-blind study duration.

Extension Treatment Period (6-12 Months):

Primary Objective:

  • Evaluate the efficacy of EryDex at two dose levels (low dose and high dose DSP/infusion) compared to placebo, in treating CNS symptoms in A-T patients during longer-term treatment (up to 12 months), as measured by the mICARS.

Secondary Objectives:

  • Evaluate the longer-term (up to 12 months) safety and tolerability of EryDex in A-T patients.
  • Compare the effects of EryDex on the CGI-C and CGI-S (structured), VABS, and QoL using the EQ-5D-5L scale.
Read the detailed description

This was an international, multi-center, one-year, randomized, prospective, double-blind, placebo-controlled, phase III study.

This study was divided into three periods: Screening (Days -30 to -1), 6-month Initial Treatment Period (Months 1-6; Visits 1-9), and 6-month Extension Treatment Period (Months 7-12; Visits 10-15).

A total of 175 patients, of the 180 planned, met all selection criteria at baseline, and were randomized in a 1:1:1 fashion to one of the two EDS-EP dose levels or placebo.

These patients were randomly assigned to receive one of the two doses of EDS-EP or placebo, as follows:

  • Group 1: EDS-EP dose range of \~5-10 mg DSP/infusion (low dose), 59 pts
  • Group 2: EDS-EP dose range of \~14-22 mg DSP/infusion (high dose), 57 pts
  • Group 3: Placebo EDS infusion, 59 pts

The initial 6-month treatment period was considered complete when the endpoint assessment (at Visit 9/Month 6 or at early discontinuation) was performed for all patients. All patients who completed the assessments over the initial 6 months of the trial were eligible to continue in an additional 6-month, double-blind, placebo- controlled extension, designed to collect information on the longer-term safety and efficacy of the trial treatments.

Following completion of the 6-month Initial Treatment Period, patients that met all entry criteria were re-randomized and treated as follows:

  • Patients originally randomized to one of the two dose levels of EryDex (low dose or high dose; Groups 1 or 2) continued in the same treatment arm.
  • Patients originally randomized to the Placebo group (Group 3) were re-allocated as defined at the initial randomization in equal proportions (1:1) and received either the EryDex low dose or high dose as follows:

    • Following 6 months of treatment, one third of the placebo patients were switched to treatment with EryDex, as described above.
    • After 9 months of treatment, another third of the placebo patients were switched to treatment with EryDex, as described above.
    • At 12 months, all remaining placebo patients were eligible to switch to open-label treatment with EryDex, as described above.
02

Conditions studied

  • Nervous System Disease
  • Genetic Syndrome

Keywords

  • Ataxia Teleangiectasia
  • AT
  • EryDex system
  • Dexamethasone
  • Dexamethasone sodium phosphate
03

In context

Nervous System Diseases

758 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.

This study's enrollment of 176 is above the median of 55 across 496 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Quince Therapeutics S.p.A. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient met clinical criteria for diagnosis of A-T. The neurological signs of A-T (incoordination of the head and eyes in lateral gaze deflection, gait ataxia associated with an inappropriately narrow base) must have been documented. Such signs of A-T illustrated the body systems in which changes were confirmed, but the listed changes were examples and other changes in those systems may have been observed and documented to confirm the diagnosis of A-T.
  2. Patient was in autonomous gait or was helped by periodic use of a support (i.e., score for Item 1 of the full ICARS - Walking Capacities between 0 and 4, included).
  3. Patient was investigated for the proven genetic diagnosis of A-T (prior documentation or by central laboratory test report).
  4. Patient was at least 6 years of age.
  5. Body weight was >15 kg.
  6. The patient and parent/caregiver (if below the age of consent), or a legal representative, provided written to participate. If consent was provided solely by the caregiver in accordance with local regulations, the patient must have provided assent to participate in the study.

Exclusion criteria

Exclusion criteria

General

  1. Females that were:

    1. Pregnant or breast-feeding (for European Union [EU] countries only).
    2. Of , pregnant, or breast-feeding (for US and Rest of World countries) not using adequate , as determined by their Healthcare Provider.
  2. A disability that may have prevented the patient from completing all study requirements.
  3. Current participation in another clinical study.

    Medical History and Current Status

  4. Cluster differential 4 positive (CD4+) lymphocytes count \<400/mm3 (for patients 6 years of age) or \<150/mm3 (for patients >6 years). In presence of oral infections, like oral candidiasis, documented at the screening or recurrent as per medical history documentation, the limit increased to \<200/mm3 (for patients >6 years).
  5. Loss/removal of 250 mL or more of blood within the past 4 weeks prior to screening.
  6. Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years.
  7. History of severe impairment of the immunological system.
  8. Severe or unstable pulmonary disease.
  9. Uncontrolled diabetes.
  10. Any other severe, unstable, or serious disease or condition that in the Investigator's opinion put the patient at risk for imminent life-threatening morbidity, need for hospitalization, or mortality.
  11. Any abnormality on standard laboratory examinations (hematology, biochemistry, urinalysis) at screening that remains abnormal on repeat testing. Eligibility of patients with abnormal laboratory test values was determined by the Investigator in consultation with the Medical Monitor.
  12. Confirmed hemoglobinopathies, e.g., C disease, sickle cell anemia, or thalassemia.
  13. Moderate or severe renal and/or hepatic impairment.

    Prior/Concomitant Medication

  14. Any previous oral or parenteral use within 4 weeks before Baseline. Treatment with inhaled or intranasal steroids for asthma or allergies, as well as use of topical steroids will be permitted.
  15. Chronic condition or prior allergic reaction representing a to the use of dexamethasone or other steroid drugs.
  16. Has participated in any other trial with an drug and received a dose within 30 days or 10 half-lives (whichever is greater) from the start of the 30-day Screening Period.
  17. Has participated in a previous trial with EryDex.
  18. Requires any concomitant medication prohibited by the protocol.
  19. Has taken a drug or treatment known to cause major organ system toxicity during the past year.
  20. Used of any drug that is a strong inducer/inhibitor of cytochrome P450 3A4 () within 4 weeks before baseline.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    EryDex Low Dose DSP

    EDS-EP dose range of \~5-10 mg DSP/infusion. This study treatment was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period). Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment). Other Names: EryDex System end product Low dose DSP

    Drug: EryDex Low dose DSP

  • Experimental
    EryDex High Dose DSP

    EDS-EP dose range of \~14-22 mg DSP/infusion. This study treatment was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period). Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment). Other Names: EryDex System end product High dose DSP

    Drug: EryDex High dose DSP

  • Placebo comparator
    Placebo

    Patients were treated with autologous erythrocytes prepared with the EDS process using a placebo solution. Placebo was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period). Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment).

    Drug: Pooled Placebo

Interventions

  • DrugEryDex Low dose DSP

    EDS-EP dose range of \~5-10 mg DSP/infusion

    Also known as: EryDex System end product

  • DrugEryDex High dose DSP

    EDS-EP dose range of \~14-22 mg DSP/infusion

    Also known as: EryDex System end product

  • DrugPooled Placebo

    EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.

    Also known as: Placebo EDS infusion

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS)

    The International Cooperative Ataxia Rating Scale (ICARS) was an assessment of the degree of impairment in patients with cerebellar ataxia and was administered in its entirety; however, the primary efficacy assessment was based on the modified (m)ICARS, which excluded the Oculomotor domain (items 17 to 19) and items 8 to 12 of the Kinetic Functions domain of the ICARS. The mICARS was a 54 points maximum score (min 0) questionnaire divided into 3 sections: * Posture and Gait Disturbance section-7 items (min score 0, max score 34) * Kinetic Function-2 items (min score 0, max score 12) * Speech Disorder- 2 items (min score 0, max score 8). The assessment was designed to be completed within 30 minutes, and higher scores - both for total and subscores - indicate a higher level of disease impairment. The subscores are added to give the total score.

    Time frame: to Month 6 (Visit 9)

Secondary outcomes

  1. Number of Patients With Improving, Stable or Worsening Score Using a Clinical Global Impression of Change (CGI-C)

    The CGI-C scale assesses the change in the patient's clinical status from baseline using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change. Clinicians were required to conduct a full clinical interview and examination of the patient. The interview and examination assessed various aspects of the patient's appearance (grooming, evidence of falls, etc.), ataxia, cognition (orientation, calculation ability, language, ability to follow commands, memory, etc.), apraxia, dysarthria, extrapyramidal motor symptoms, activities of daily living, and mood. The higher the score the worse the outcome.

    Time frame: to Month 6 (Visit 9)

  2. Number of Patients With None to Severe (0 to 4) Scores in Clinical Global Impression of Severity (CGI-S)-Structured of Neurological Symptoms of AT

    The CGI-S scale measures global severity of illness at a given point in time, and is usually rated on a 7-point, Likert-type scale ranging from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). No version of the CGI-S exists which has been specifically adapted for use in patients with A-T; therefore, a 5-point version was developed that considered the severity of the following symptoms of A-T: ataxia (walking), dysarthria, dysmetria, extrapyramidal symptoms (chorea, myoclonus, dystonia, and tremor), and eye movements. Ratings of none (0), mild (1), moderate (2), severe (3), and very severe (4) were selected based on the level of symptomatology. The higher the score the worse the outcome.

    Time frame: to Visit 9 (Month 6)

  3. Change From Baseline of Vineland Adaptive Behavior Scale (VABS-II) Scores - Last Observation Carried Forward (LOCF)

    VABS-II was a questionnaire to assess adaptive behavior. It contained 4 domains each with 2-3 subdomains, every subdomain contained various items (questions): A) communication (receptive, expressive, written) B) daily living skills (personal, domestic, community) C) socialization (interpersonal relationships, play and leisure time, coping skills) D) motor skills (gross motor, fine motor). The expanded version of the VABS consisted of 540 items, 261 of which used in this trial. The possible score for each item was from 0 to 4 based on whether the patient performed the activity "never", "rarely", "sometimes", "often" or "almost always". At the end of each domain section, a total score (the sum of the score for each item) was calculated. Domain A: min score 0, max score 572. Domain B: 0 - 800. Domain C: 0 - 580. Domain D: 0 - 424. A grand total score (A+B+C+D scores) was provided (range:0-2376) The lower the score the higher the disability at each level (domains and subdomains).

    Time frame: to Visit 9 (Month 6)

  4. Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) at Month 6

    TEAE = Treatment Emergent Adverse Events were any AEs started on or after the day of the first infusion through the day just prior to the day of the Visit 9 ("Month 6") infusion, or \<=60 days after last dose if the subject never continued past this period.

    Time frame: to Visit 9 (Month 6)

  5. Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) at Month 12

    TEAE = Treatment Emergent Adverse Events were any AEs started on or after the day of the first infusion through the day just prior to the day of the Visit 15 ("Month 12") infusion. Placebo patients who switched to EryDex treatment at 6 and 9 months were not added to the Extension Treatment Period safety data so that the results reported here under are for those patients who remained on placebo from the start of the study till the end of it.

    Time frame: to Visit 15 (Month 12)

07

Results

Posted May 9, 2024

Participant flow

176 patients were randomized, and 175 patients received study drug (Safety Population or ITT). There were 164 patients in the mITT and 107 patients in the PP population. Of the 164 patients in the mITT, 54 were randomized to placebo, 56 to low dose, and 54 to high dose EryDex.The PP population excluded 57 patients that were unable to comply with the study treatment interval, mainly due to the COVID-19 pandemic and issues with traveling in India, and who did not meet the definition of the PP.

Participant flow — Overall Study
MilestoneEryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFPooled Placebo - SAF
Started595859
Participants who took the study drug595759
Modified intention to treat population - mitt565454
Safety population - saf595759
Per protocol population - pp363833
Completed visit 9434643
Discontinued prior to visit 9161116
Participants from month 6 to month 9434643
Participants from month 9 to month12343836
Completed343836
Not completed252023
Withdrew: Adverse event331
Withdrew: Withdrawal by subject734
Withdrew: Other010
Withdrew: Covid-related treatment/visit delay151317
Withdrew: Physician decision001

Outcome measures

PrimaryChange From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS)

The International Cooperative Ataxia Rating Scale (ICARS) was an assessment of the degree of impairment in patients with cerebellar ataxia and was administered in its entirety; however, the primary efficacy assessment was based on the modified (m)ICARS, which excluded the Oculomotor domain (items 17 to 19) and items 8 to 12 of the Kinetic Functions domain of the ICARS. The mICARS was a 54 points maximum score (min 0) questionnaire divided into 3 sections: * Posture and Gait Disturbance section-7 items (min score 0, max score 34) * Kinetic Function-2 items (min score 0, max score 12) * Speech Disorder- 2 items (min score 0, max score 8). The assessment was designed to be completed within 30 minutes, and higher scores - both for total and subscores - indicate a higher level of disease impairment. The subscores are added to give the total score.

Time frame:
to Month 6 (Visit 9)
Reported as:
Mean · score on a scale
Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS)
score on a scaleEryDex Low Dose DSP - mITTEryDex High Dose DSP - mITTPlacebo - mITT
Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS)0.8 ± 3.561.0 ± 3.322.3 ± 5.03
Statistical analysis
  • EryDex Low Dose DSP - mITT vs Placebo - mITT · Mixed model for repeated measures · p = 0.0847 · Least squares mean difference: -1.37 · 95% CI -2.932 to 0.190
  • EryDex High Dose DSP - mITT vs Placebo - mITT · Mixed model for repeated measures · p = 0.0765 · Least squares mean difference: -1.40 · 95% CI -2.957 to 0.152
SecondaryNumber of Patients With Improving, Stable or Worsening Score Using a Clinical Global Impression of Change (CGI-C)

The CGI-C scale assesses the change in the patient's clinical status from baseline using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change. Clinicians were required to conduct a full clinical interview and examination of the patient. The interview and examination assessed various aspects of the patient's appearance (grooming, evidence of falls, etc.), ataxia, cognition (orientation, calculation ability, language, ability to follow commands, memory, etc.), apraxia, dysarthria, extrapyramidal motor symptoms, activities of daily living, and mood. The higher the score the worse the outcome.

Time frame:
to Month 6 (Visit 9)
Reported as:
Count of participants · Participants
Number of Patients With Improving, Stable or Worsening Score Using a Clinical Global Impression of Change (CGI-C)
ParticipantsEryDex Low Dose DSP - mITTEryDex High Dose DSP - mITTPlacebo - mITT
Improvement (Scores 1-3)192719
Stable or Worsening (Scores 4-7)372735
Statistical analysis
  • EryDex Low Dose DSP - mITT vs Placebo - mITT · Regression, Logistic · p = 0.8919 · Odds ratio (or): 0.946 · 95% CI 0.426 to 2.099
  • EryDex High Dose DSP - mITT vs Placebo - mITT · Regression, Logistic · p = 0.1255 · Odds ratio (or): 1.848 · 95% CI 0.842 to 4.053
SecondaryNumber of Patients With None to Severe (0 to 4) Scores in Clinical Global Impression of Severity (CGI-S)-Structured of Neurological Symptoms of AT

The CGI-S scale measures global severity of illness at a given point in time, and is usually rated on a 7-point, Likert-type scale ranging from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). No version of the CGI-S exists which has been specifically adapted for use in patients with A-T; therefore, a 5-point version was developed that considered the severity of the following symptoms of A-T: ataxia (walking), dysarthria, dysmetria, extrapyramidal symptoms (chorea, myoclonus, dystonia, and tremor), and eye movements. Ratings of none (0), mild (1), moderate (2), severe (3), and very severe (4) were selected based on the level of symptomatology. The higher the score the worse the outcome.

Time frame:
to Visit 9 (Month 6)
Reported as:
Count of participants · Participants
Number of Patients With None to Severe (0 to 4) Scores in Clinical Global Impression of Severity (CGI-S)-Structured of Neurological Symptoms of AT
ParticipantsEryDex Low Dose DSP - mITTEryDex High Dose DSP - mITTPlacebo - mITT
CGI-S Score - 0000
CGI-S Score - 1151617
CGI-S Score - 2292624
CGI-S Score - 3121213
CGI-S Score - 4000
Statistical analysis
  • EryDex Low Dose DSP - mITT vs Placebo - mITT · Ordinal Logistic Regression Analysis · p = 0.4583 · Odds ratio (or): 1.369 · 95% CI 0.597 to 3.144
  • EryDex High Dose DSP - mITT vs Placebo - mITT · Ordinal Logistic Regression Analysis · p = 0.4585 · Odds ratio (or): 1.371 · 95% CI 0.595 to 3.160
SecondaryChange From Baseline of Vineland Adaptive Behavior Scale (VABS-II) Scores - Last Observation Carried Forward (LOCF)

VABS-II was a questionnaire to assess adaptive behavior. It contained 4 domains each with 2-3 subdomains, every subdomain contained various items (questions): A) communication (receptive, expressive, written) B) daily living skills (personal, domestic, community) C) socialization (interpersonal relationships, play and leisure time, coping skills) D) motor skills (gross motor, fine motor). The expanded version of the VABS consisted of 540 items, 261 of which used in this trial. The possible score for each item was from 0 to 4 based on whether the patient performed the activity "never", "rarely", "sometimes", "often" or "almost always". At the end of each domain section, a total score (the sum of the score for each item) was calculated. Domain A: min score 0, max score 572. Domain B: 0 - 800. Domain C: 0 - 580. Domain D: 0 - 424. A grand total score (A+B+C+D scores) was provided (range:0-2376) The lower the score the higher the disability at each level (domains and subdomains).

Time frame:
to Visit 9 (Month 6)
Reported as:
Mean · score on a scale
Change From Baseline of Vineland Adaptive Behavior Scale (VABS-II) Scores - Last Observation Carried Forward (LOCF)
score on a scaleEryDex Low Dose DSP - mITTEryDex High Dose DSP - mITTPlacebo - mITT
Change From Baseline of Vineland Adaptive Behavior Scale (VABS-II) Scores - Last Observation Carried Forward (LOCF)42.6 ± 125.95-26.5 ± 214.5257.5 ± 200.37
Statistical analysis
  • EryDex Low Dose DSP - mITT vs Placebo - mITT · ANCOVA · p = 0.7029 · Least squares means difference: -13.33 · 95% CI -82.261 to 55.601
  • EryDex High Dose DSP - mITT vs Placebo - mITT · ANCOVA · p = 0.0328 · Least squares means difference: -77.31 · 95% CI -148.201 to -6.421
SecondaryNumber of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) at Month 6

TEAE = Treatment Emergent Adverse Events were any AEs started on or after the day of the first infusion through the day just prior to the day of the Visit 9 ("Month 6") infusion, or \<=60 days after last dose if the subject never continued past this period.

Time frame:
to Visit 9 (Month 6)
Reported as:
Count of participants · Participants
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) at Month 6
ParticipantsEryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFPooled Placebo - SAF
Patients With Pre- treatment AE141614
Patients With Any TEAE434743
Patients With Any Treatment-related TEAE152115
Patients With Any Serious TEAE677
Patients With Any Serious Treatment-related TEAE010
Patients With Any TEAE Leading to Discontinuation020
Patients With Any TEAE Leading to Death000
SecondaryNumber of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) at Month 12

TEAE = Treatment Emergent Adverse Events were any AEs started on or after the day of the first infusion through the day just prior to the day of the Visit 15 ("Month 12") infusion. Placebo patients who switched to EryDex treatment at 6 and 9 months were not added to the Extension Treatment Period safety data so that the results reported here under are for those patients who remained on placebo from the start of the study till the end of it.

Time frame:
to Visit 15 (Month 12)
Reported as:
Count of participants · Participants
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) at Month 12
ParticipantsEryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFNon-switch Placebo - SAF
Patients With Any TEAE455015
Patients With Any Treatment-related TEAE19255
Patients With Any Serious TEAE894
Patients With Any Serious Treatment-related TEAE111
Patients With Any TEAE Leading to Discontinuation120
Patients With Any TEAE Leading to Death000

Adverse events

Collected over TEAEs were all the AEs reported up to the end of the Extension Treatment Period (Month 12). All AEs with an onset date on/after the start of the first infusion through 60 days after the last dose are included. A patient with more than one event with the same SOC is counted once. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EryDex Low Dose DSP - SAF0/59 (0%)8/59 (13.6%)45/59 (76.3%)
EryDex High Dose DSP - SAF0/57 (0%)9/57 (15.8%)50/57 (87.7%)
Non-switch Placebo - SAF1/19 (5.3%)4/19 (21.1%)15/19 (78.9%)
Placebo Patients Switch to Low Dose - Month 60/9 (0%)1/9 (11.1%)7/9 (77.8%)
Placebo Patients Switch to High Dose - Month 60/9 (0%)1/9 (11.1%)8/9 (88.9%)
Placebo Patients Switch to Low Dose - Month 90/11 (0%)1/11 (9.1%)7/11 (63.6%)
Placebo Patients Switch to High Dose - Month 90/11 (0%)4/11 (36.4%)9/11 (81.8%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventEryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFNon-switch Placebo - SAFPlacebo Patients Switch to Low Dose - Month 6Placebo Patients Switch to High Dose - Month 6Placebo Patients Switch to Low Dose - Month 9Placebo Patients Switch to High Dose - Month 9
Bacterial test positiveInvestigations4/596/573/191/90/91/112/11
PyrexiaGeneral disorders0/591/570/190/91/90/110/11
Hepato-Lenticular DegenerationCongenital, familial and genetic disorders0/590/570/190/90/90/111/11
VomitingGastrointestinal disorders0/590/570/190/90/90/111/11
Juvenile idiophatic arthritisMusculoskeletal and connective tissue disorders0/590/571/190/90/90/110/11
AnaemiaBlood and lymphatic system disorders0/591/570/190/90/90/110/11
SepsisInfections and infestations0/591/570/190/90/90/110/11
Aortic stenosisVascular disorders0/591/570/190/90/90/110/11
Herpes ZosterInfections and infestations1/590/570/190/90/90/110/11
Lower respiratory tract infectionInfections and infestations1/590/570/190/90/90/110/11
Most frequent other events
Showing 10 of 146
Most frequent other events
EventEryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFNon-switch Placebo - SAFPlacebo Patients Switch to Low Dose - Month 6Placebo Patients Switch to High Dose - Month 6Placebo Patients Switch to Low Dose - Month 9Placebo Patients Switch to High Dose - Month 9
CoughRespiratory, thoracic and mediastinal disorders10/5913/576/191/94/93/111/11
PyrexiaGeneral disorders15/5919/573/193/92/94/112/11
DiarrhoeaGastrointestinal disorders8/596/575/190/90/93/110/11
Bacterial test positiveInvestigations10/5910/574/191/92/91/113/11
NasopharyngitisInfections and infestations10/5911/575/191/91/91/111/11
Weight increasedInvestigations0/591/570/192/90/90/110/11
HeadacheNervous system disorders8/595/572/192/90/91/112/11
VomitingGastrointestinal disorders13/5911/573/190/91/91/112/11
Abdominal pain upperGastrointestinal disorders0/590/570/191/90/90/112/11
Blood iron decreasedInvestigations0/590/570/190/90/92/111/11

Baseline characteristics

Safety (SAF): all patients who received any amount of randomized treatment (also referred to as the ITT ) Full Analysis Set (FAS): All randomized pts who received at least 1 dose of study medication and had at least one post-baseline efficacy assessment of the primary efficacy variable (also referred to as mITT ) Per Protocol (PP): all pts enrolled fulfilled all Inclusion/Exclusion criteria, did not have any major protocol violations, and completed the Initial Treatment Period of the study

Age, Categorical
Age, Categorical(Participants)EryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFPooled Placebo - SAFTotal
<=18 years595759175
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)EryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFPooled Placebo - SAFTotal
Mean9.5 ± 3.1610.2 ± 4.8610.3 ± 4.0210.0 ± 4.06
Sex: Female, Male
Sex: Female, Male(Participants)EryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFPooled Placebo - SAFTotal
Female29272985
Male30303090
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFPooled Placebo - SAFTotal
American Indian or Alaska Native0000
Asian25202772
Native Hawaiian or Other Pacific Islander0000
Black or African American0123
White34362999
More than one race0011
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)EryDex Low Dose DSP - SAFEryDex High Dose DSP - SAFPooled Placebo - SAFTotal
Belgium1203
United States11121032
Norway2215
Poland35311
United Kingdom23611
Italy1214
Israel1001
Australia1315
Tunisia3328
Germany56516
Spain72413
India22182666
08

Study locations

22 sites
  • UCLA-Ataxia Center and HD Center of Exellence
    Los Angeles, California 900951694, United States
  • The Ataxia-Telangiectasia Clinical Center, The Johns Hopkins Hospital
    Baltimore, Maryland 21287-3923, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • UT Health
    Houston, Texas 77030, United States
  • Royal Children's Hospital
    Melbourne, Victoria 3052, Australia
  • Laboratoriumgeneeskunde
    Leuven, 3000, Belgium
  • Klinik für Kinder- und Jugendmedizin Pädiatrische Allergologie, Pneumologie und Mukoviszidose, Universitätsklinikum Frankfurt
    Frankfurt, Hessen 60590, Germany
  • National Institute of Mental Health and Neurosciences
    Bangalore, Karnataka 560 029, India
  • Amrita Institute of Medical Sciences and Research Centre
    Kochi, Kerala 682041, India
  • Jaslok Hospital and Research Centre
    Mumbai, Maharashtra 400026, India
  • PD Hinduja National Hospital and Medical Research
    Mahim, Mumbai 400016, India
  • Vijaya Health Centre, Department of Neurology
    Chennai, Tamil Nadu 600026, India
  • Nizam's Institute of Medical Sciences
    Hyderabad, Telangana 500082, India
  • All India Institute of Medical Sciences
    New Delhi, 110029, India
  • Sheba Medical Center
    Tel HaShomer, 52621, Israel
  • U.O. Neurologia e Psichiatria dell'Infanzia e dell' Adolescenza. ASST Spedali Civili, Piazzale Spedali Civili, 1
    Brescia, 25123, Italy
  • Dipartimento di Pediatria e Neuropsichiatria Infantile, Università Sapienza di Roma, Azienda Policlinico Universitario Umberto I
    Rome, 00185, Italy
  • Norwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo University Hospital
    Oslo, Norway
  • Department of Clinical Immunology The Children's Memorial Health Institute
    Warsaw, 04-730, Poland
  • Hospital Universitario La Paz.
    Madrid, Spain
  • El Razi Hospital
    Manouba, 2010, Tunisia
  • Nottingham University Hospitals NHS Trust - Queen's Medical Centre
    Nottingham, Nottinghamshire, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in May 2021, 50 months.

Results were first posted in May 2024, 2 years 11 months after primary completion.

Of 36 industry-sponsored phase 3 interventional studies under Nervous System Diseases, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 56. This study's 50 months is above that.

Counting every sponsor, half of 40 studies reached it within 42 months; a quarter within 28 and three quarters within 55.

Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2016
First posted
May 12, 2016
StartActual
Mar 2, 2017
Primary completionActual
May 13, 2021
CompletionActual
May 13, 2021
Results first posted
May 9, 2024
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02770807
Lead sponsor
Quince Therapeutics S.p.A.
Responsible party
Sponsor
First posted
May 12, 2016
Start date
Mar 2, 2017
Primary completion
May 13, 2021
Completion
May 13, 2021
Results posted
May 9, 2024
Last update
May 10, 2024

Study contacts

Guenter R. Janhofer, MD, PhD
study director · EryDel S.p.A

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion